Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the commencement of a commercial clinical trial on its proprietary drug candidate BMND06, a novel formulation based on the psychedelic molecule mescaline.

“As we advance on the sustainable and biological synthesis of the active pharmaceutical ingredient mescaline, we are starting the first phase of a commercial clinical trial towards the registration of “Triptax® M” under the United States Food and Drug Administration and the European Medicines Agency. This is another firm step by the Company towards entering into commercial clinical trials,”

Alejandro Antalich, CEO of Biomind Labs.

“With the confidence that precedes us, we leave our comfort zone, which is based in the tryptamines DMT and 5-MeO-DMT, to bring a new psychedelic molecule, based on mescaline, to market. After a deep and rigourous evaluation of the potential of this new molecule, that may go beyond addressing mental health conditions, we have strategically decided to take the challenge of advancing a commercial clinical trial with our proprietary drug candidate which targets inflammation, a condition that we consider to be responsible for several types of depression.

“BMND06 is an almost unexplored molecule within a tailor-made program that has the potential to break psychedelic stereotypes and possibly provide us with new avenues to keep exploring the medicinal power of several psychedelic molecules with the further possibility of treating several indications. We believe that we currently have one of the most original and diversified portfolios in the psychedelic industry, which consists of three molecules from two different families, seven indications and five drug delivery systems, all combined with a robust intellectual property portfolio,” concluded Alejandro Antalich, CEO of Biomind Labs.

Mescaline is a naturally occurring psychedelic compound which has received recognition of its possible therapeutic benefits for many decades. Mescaline acts similar to other psychedelic agents by binding to, and activating, the serotonin 5-HT2A receptor with high affinity.

Biomind Labs has entered into an agreement with one of the most prestigious and experienced clinical trial institutions, Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, to conduct its first commercial clinical trial. This engagement will help to ensure that the clinical trials align with the principles of Good Clinical Practices and the highest ethical and quality standards.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (“DMT”), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.